Shanghai Symray Biopharma Co. Ltd, established in 2019, is a biotech company focusing on research and development (R&D) of innovative antibody-based therapeutics. By using our well-established platforms including 1) the all-species, all-epitope, and full-function antibody discovery platform, 2) the high-throughput, automated antibody identification platform and 3) the systematic, personalized drug verification platform, Symray constantly develop various mAbs, bi-specific Abs, antibody–drug conjugates and antibody fusion proteins, etc for unmet clinical needs.

Echo with the mission of "establishing a new R&D paradigm for innovative therapeutics", we are committed to linking innovation entities in the drug discovery community, by providing a platform of technology transfer for creative scientists, and high-quality drug pipelines for pharmaceutical companies. We currently have 30+ products in the pipeline, 200+ targets under development, and 20+ established external cooperation. Our talented R&D team, state of art technology platforms, and sufficient readily available products enable us to thrive in the highly competitive early drug discovery market.